Recent works revealed that STAT5 overexpression leads to a TKI-resistant phenotype, an effect that is independent of JAK2 expression, and that targeting STAT5 by drugs, like the neuroleptic drug pimozide [23] might be a promising perspective in the pharmacology of leukemia and other cancers as well. This evidence concerns the gene STAT5A and cancer.